Hims & Hers Health, Inc.
Company Stats
- Market Cap
- $7.0B
- as of Sep 30, 2026
- Shares Outstanding
- 233.3M
- Free Float
- 72.3%
Income Statement
- Revenue
- $2.3B
- Operating Income
- $105.6M
- Net Income
- $128.4M
- EBITDA
- $160.1M
- Revenue Growth, 3Y
- 64.5%
- FCF Margin, 3Y Avg
- 7.1%
- FCF Margin, Worst Year
- 2.4%
Cash Flow
- Free Cash Flow
- $57.4M
- FCF Yield
- 0.8%
- Owner FCF Yield
- -1.1%
Balance Sheet
- Cash & Equivalents
- $228.6M
Returns & Capital
- Share Repurchases
- $90.0M
- Buyback Yield, 3Y Avg
- 0.8%
- SBC, 3Y Avg
- $97.9M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $2.3B | $57.4M | 2.4% |
| FY2024 | $1.5B | $198.3M | 13.4% |
| FY2023 | $872.0M | $47.0M | 5.4% |
| FY2022 | $526.9M | -$33.7M | -6.4% |
| FY2021 | $271.9M | -$34.4M | -12.7% |
Annual filing data through FY ended December 31, 2025; shares and float as of October 14, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Earnings
Other Coverage
October 14, 2026
Theme Survey
GLP-1 companies reshape access and detail treatment dropouts
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 4, 2026
Theme Survey
GLP-1 Shift: Branded Access and Oral Formulations Gain Ground
June 2, 2026
Deals
Hims & Hers to Buy Eucalyptus in Global Expansion Deal
GLP-1 companies reshape access and detail treatment dropouts
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 4, 2026
Theme Survey
GLP-1 Shift: Branded Access and Oral Formulations Gain Ground
June 2, 2026
Deals
Hims & Hers to Buy Eucalyptus in Global Expansion Deal